Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271282 · ClinicalTrials.gov registry record · Phase 1
Estradiol-Receptor Blockade in Older Men and Women
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02271282: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02271282 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02271282, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Repletion of testosterone (Te) in older men drives GH secretion after its aromatization to estradiol (E2), which acts via the estrogen receptor (ER). Conversely, we postulate that estrogen deprivation in postmenopausal women attenuates growth hormone (GH) secretion and insulin-like growth factor-1 (IGF-I) production, thus favoring development of metabolic syndrome in men treated with toremifene, a new estrogen antagonist used adjunctively in prostatic cancer
Interventions
- DRUG Placebo
- DRUG Toremifene
- DRUG GHRH/Ghrelin combined Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02271282
The ClinicalTrials.gov registry entry for NCT02271282 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02271282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02271282 about?
NCT02271282 is a clinical study titled "Estradiol-Receptor Blockade in Older Men and Women". Repletion of testosterone (Te) in older men drives GH secretion after its aromatization to estradiol (E2), which acts via the estrogen receptor (ER). Conversely, we postulate that estrogen deprivation in postmenopausal women attenuates growth hormone (GH) secretion and insulin-like growth factor-1 (...
What is the current status of trial NCT02271282?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-12. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02271282?
The interventions under investigation include: Placebo (DRUG), Toremifene (DRUG), GHRH/Ghrelin combined Injection (DRUG).
Who is sponsoring clinical trial NCT02271282?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.